Table 2.
Summary of gamma-secretase inhibitors (GSI) under clinical development in oncology.
| GSI | Company | Clinical status | Reference |
|---|---|---|---|
| BMS-906024 (AL101) | Bristol Myers Squibb (BMS) | 2 | Chan et al (40) |
| BMS-986115 (AL102) | Bristol Myers Squibb (BMS) | 2 | Aung et al (41) |
| LY-900009 | Eli Lilly | 1 | Pant et al (42) |
| MK-0752 | Merck | 2 | Cook et al (43) |
| PF-03084014 (Nirogacestat) | Pfizer | 3 | Kummar et al (44), Takahashi et al (45) |
| RO4929097 (RG-4733) | Roche | 2 | Lee et al (46), Sahebjam et al (47) |